CERo Therapeutics Holdings (CERo Therapeutics Holdings) Tax Expense : $ Mil (TTM As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Tax Expense?

CERo Therapeutics Holdings's tax expense for the six months ended in Dec. 2022 was $0.00 Mil.

CERo Therapeutics Holdings Tax Expense Historical Data

The historical data trend for CERo Therapeutics Holdings's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Tax Expense Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Tax Expense

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Tax Expense	-	-

CERo Therapeutics Holdings Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

CERo Therapeutics Holdings (NAS:CERO) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.

CERo Therapeutics Holdings Tax Expense Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Tax Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024